2024 Latin America Conference on Lung Cancer (LALCA) - Posters-PP01.26: Five Years (5y) Overall Survival (OS) With Targeted Therapy (TT) in Patients (pts) With Non-Small Cell Lung Cancer (aNSCLC) at a Comprehensive Cancer Center (CCC) in Colombia

PP01.26: Five Years (5y) Overall Survival (OS) With Targeted Therapy (TT) in Patients (pts) With Non-Small Cell Lung Cancer (aNSCLC) at a Comprehensive Cancer Center (CCC) in Colombia

Back to course

Pdf Summary

This study, conducted by a team at the Centro Integral de Cáncer, Clínica de Occidente in Cali, Colombia, aimed to evaluate the 5-year overall survival (OS) of advanced non-small cell lung cancer (NSCLC) patients treated with immunotherapy (IO). It focused on patients with advanced NSCLC without actionable mutations, treated at a cancer care center in a resource-limited setting.<br /><br />A retrospective analysis was performed on 134 patients with NSCLC, with complete clinical data and long-term follow-up from 2013 to 2023. The study used Kaplan-Meier and Cox regression analyses to determine survival outcomes and assess the association of relevant variables with survival.<br /><br />The results showed that the 5-year OS was significantly higher in patients who received IO (22%) compared to those who did not (2%). Using IO reduced the risk of death by 62% (HR 0.38). Other factors significantly associated with increased mortality included poorer ECOG performance status (HR 1.74) and certain histological subtypes (HR 1.28). Male patients showed a non-significant trend towards higher mortality (HR 1.3). No significant associations with mortality were found regarding health insurance type, age, or rural living.<br /><br />The study concludes that immunotherapy significantly improves survival even in resource-limited settings when patients are appropriately selected. It highlights the need for making IO more accessible to improve patient outcomes, stressing the importance of individualized patient treatment plans. The findings reflect real-world data from Colombia, providing valuable insights into the impact of contemporary cancer therapies in diverse healthcare environments.<br /><br />These conclusions underscore the potential for immunotherapy to extend survival in patients with advanced NSCLC when integrated into treatment regimens, emphasizing that access to such treatments is crucial even in less affluent populations.

Asset Subtitle

Sergio Cafiero

Keywords

immunotherapy

non-small cell lung cancer

overall survival

resource-limited settings

Kaplan-Meier analysis

Cox regression

ECOG performance status

Colombia

cancer care

personalized treatment